| [1] |
Fruman DA,Rommel C.PI3K and cancer:lessons,challenges and opportunities[J].Nat Rev Drug Disc,2014,13(2):140-156.
|
| [2] |
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms,modes of activation and therapeutic targeting[J].Nat Rev Canner,2015,15(1):7-24.
|
| [3] |
Puri KD,Di Paolo JA,Gold MR.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies[J].Int Rev Immunol,2013,32(4):397-427.
|
| [4] |
Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta:modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies[J].Front Immunol,2012,3:256.
|
| [5] |
Angulo I,Vadas O,Garcon F.Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage[J].Science,2013,342(6160):866-871.
|
| [6] |
Shao T,Wang J,Chen JG,et al.Discovery of 2-methoxy-3-phenylsufonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere[J].Eur J Med Chem,2014,75:96-105.
|
| [7] |
Wei M,Wang X,Song Z,et al.Targeting PI3Kδ:emerging therapy for chronic lymphocytic leukemia and beyond[J].Med Res Rev,2015,35(4):720-752.
|
| [8] |
Venable JD, Ameriks MK. Small molecule inhibitors of phosphoinositide 3-kinase(PI3K)δ and γ[J].Curr Top Med Chem,2009,9(8):738-753.
|
| [9] |
Norman P.Selective PI3Kδ inhibitors,a review of the patent literature[J].Expert Opin Ther Pat,2011,21(11):1773-1790.
|
| [10] |
Norman P.Evaluation of WO201313136076:two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729[J].Expert Opin Ther Pat,2013,24(4):471-475.
|
| [11] |
Norman P. Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma[J].Expert Opin Ther Pat,2014,24(5):603-607.
|
| [12] |
Markham A.Idelalisib:first global approval[J].Drugs,2014,74(14):1701-1707.
|
| [13] |
Fruman DA,Cantley LC.Idelalisib a PI3Kδ inhibitor for B-cell cancers[J].N Engl J Med,2014,370(11):1061-1062.
|
| [14] |
Okkenhaug K.Two birds with one stone:dual p110δ and p110γ inhibition[J].Chem Biol,2013,20(11):1309-1310.
|
| [15] |
TG Therapeutics.TG-1101(Ublituximab)references[EB/OL].http://www.tgtherapeutics.com/pipeline/publications.cfm.
|
| [16] |
Vakkalanka S,Viswanadha S,Gaudio E,et al.Dual PI3Kδ/γ inhibition by RP6530 induces apoptosis and cytotoxicity in B-lymphoma cells[J].Blood,2013,122(21):4411.
|
| [17] |
Cushing TD,Hao X,Shin Y,et al.Discovery and in vivo evaluation of(s)-N-(1-(7-fluoro-2-(pyridine-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine(AMG319)and related PI3Kδ inhibitors for inflammation and autoimmune disease[J].J Med Chem,2015,58(1):480-511.
|
| [18] |
Safina BS,Baker S,Baumgardner M,et al.Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis:taming CYP3A4 time-dependent inhibition[J].J Med Chem,2012,55(12):5887-5900.
|
| [19] |
Murray JM,Sweeney ZK,Chan BK,et al.Potent and highly selective benzimidazole inhibitors of PI3-kinase delta[J].J Med Chem,2012,55(17):7686-7695.
|
| [20] |
Safina BS,Sweeney ZK,Li J,et al.Identification of GNE-293,a potent and selective PI3Kδ inhibitor:navigating in vitro genotoxicity while improving potency and selectivity[J].Bioorg Med Chem Lett,2013,23(17):4953-1959.
|
| [21] |
Down K, Amour A, Baldwin IR, et al. Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease[J].J Med Chem,2015,58(18):7381-7399.
|
| [22] |
Haselmayer P,Camps M,Muzerelle M.Characterization of novel of PI3Kδ inhibitors as potentical therapeutics for SLE and lupus nephritis in pre-clinical studies[J].Front Immunol,2014,5:233.
|
| [23] |
Cushing TD,Metz DP,Whittington DA,et al.PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases[J].J Med Chem,2012,55(20):8559-8581.
|
下载:
